Pneumonia drug candidate wins fast-track designation from FDA

04/29/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track status to Sanofi Pasteur and KaloBios Pharmaceuticals' KB001A, an experimental treatment for Pseudomonas aeruginosa-related pneumonia among people being treated with mechanical ventilation. The drug, a monoclonal antibody, is undergoing an early-stage study in the U.S.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY